Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Andiabet in Type 2 Diabetes Mellitus
NCT04930679Phase 1Completed
- Start
- Nov 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM). Primary endpoint: Adverse events at 28 days. Started Nov 2018; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04930679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04930679.